Claims
- 1. A method of treating either CD33+ acute myeloid leukemia CD33+ chronic myeloid leukemia in mammals including humans, using at least one of water:methanol fraction nos. 1 and 9, which have been obtained from a polar extract of the plant piper betel by HPLC, with a retention time of 3.6 and 24.0 minutes rescpectively, wherein at least one fraction is used either individually, or in combination, said method comprising the steps of administering an effective amount of at least one fraction intravenously to a patient suffering from myeloid leukemia.
- 2. A method as claimed in claim 1, wherein a ratio of water to methanol ranges between approximately 1:5 to 5:1.
- 3. A method as claimed in claim 1, wherein fraction no. 9 is used which essentially comprises the compound 3-O-p-coumaryl quinic acid.
- 4. A method as claimed in claim 3, wherein the compound 3-O-p-coumaryl quinic acid of fraction no. 9 is used in an effective amount in acute myeloid leukemia.
- 5. A method as claimed in claim 3, wherein the compound 3-O-p-coumaryl quinic acid of fraction 9 is purified, and an effective amount exhibits about 100% efficacy against acute myeloid leukemia, at a concentration of about 600 μg/ml.
- 6. A method as claimed in claim 1, wherein a dosage of an effective amount of at least one fraction individually ranges between 200-500 mg/day.
- 7. A method as claimed in claim 1, wherein a dosage of an effective amount of fraction nos. 1, and 9 in combination ranges between 125 to 370 mg/day.
- 8. A method as claimed in claim 1, wherein the ratio for a dosage of an effective amount of fraction nos. 1 and 9 ranges between 0.1:5 to 5:0.1, and is preferably about 1:1.
- 9. A method as claimed in claim 1, wherein an effective amount of fraction 1 is more efficient as compared to an effective amount of fraction 9.
- 10. A method as claimed in claim 1, wherein an effective amount of a combination of fractions 1 and 9 is more efficient in the management of myeloid leukemia as compared to an effective amount of each fraction alone.
- 11. A composition useful for treating either CD33+ acute myeloid leukemia or CD33+ chronic myeloid leukemia in mammals including humans, said composition comprising water:methanol fraction nos. 1 and 9, which have been obtained from a polar extract of the plant piper betel by HPLC, with a retention time of 3.6 and 24.0 minutes respectively, wherein at least one fraction is present either individually or in combination.
- 12. A composition as claimed in claim 11, wherein the fraction 9 essentially comprises the compound 3-O-p-coumaryl quinic acid.
- 13. A method of isolating biologically active fraction nos. 1 and 9 from the water:methanol fraction, which have been obtained from a polar extract of the plant piper betel, said method comprising the steps of:
a. cutting the plant parts into small pieces, b. homogenizing the said pieces with polar solvent to obtain an extract, c. filtering the extract to collect filterate, d. lyophilizing the clear extract solution to obtain a semi-solid mass, e. fractionating the said semi-solid mass using column chromatography with only water, water-methanol with ratio ranging between 1:5 to 5:1, and only methanol, as eluents, f. selecting water:methanol fraction from the column chromatography, g. running HPLC with flow rate of 1.0 ml/min, using solvent system of methanol:water:acetic acid of ratio about 23:76:1, h. detecting about 12 peaks at about 280 nm, with varied retention time ranging between 3.6 to 36 minutes, i. separating the said peaks in a preparative HPLC with flow rate of 12 ml/min, and j. obtaining fraction nos. 1 and 9 having desired biological activity.
- 14. A method as claimed in claim 13, wherein the fraction 9 essentially comprises compound 3-O-p-coumaryl quinic acid.
- 15. A method as claimed in claim 13, wherein the filtrate is centrifuged to obtain a clear solution before the fractionating step.
- 16. A method as claimed in claim 13, wherein ratio of dosage of fraction nos. 1 and 9 ranges between approximately 0.1:5 to 5:0.1, and preferably is 1:1.
- 17. A method of treating either CD33+ acute myeloid leukemia or CD33+ chronic myeloid leukemia in mammals including humans, using compound 3-O-p-coumaryl quinic acid obtained from the fraction 9 of polar extract of piper betel by HPLC, with retention time of about 24.0 minutes, said method comprising steps of administering an effective amount of the fraction intravenously to a patient suffering from myeloid leukemia.
- 18. A method as claimed in claim 17, wherein an effective amount of the compound 3-O-p-coumaryl quinic acid exhibits about 100% efficacy against acute myeloid leukemia, at a concentration of about 600 μg/ml.
- 19. A method as claimed in claim 17, wherein an effective amount of the compound 3-O-p-coumaryl quinic acid exhibits about 85% efficacy against chronic myeloid leukemia, at a concentration of about 600 μg/ml.
- 20. A method as claimed in claimed in claim 17, wherein an effective amount of the compound 3-O-p-coumaryl quinic acid exhibits about 60% efficacy against acute myeloid leukemia, at a concentration of about 100 μg/ml.
- 21. A method as claimed in claim 17, wherein an effective amount of a concentration of compound 3-O-p-coumaryl quinic acid ranges between 50-700 μg/ml.
Parent Case Info
[0001] This application claims benefit of U.S. Provisional Application No. 60/384,163 filed May 31, 2002
Provisional Applications (1)
|
Number |
Date |
Country |
|
60384163 |
May 2002 |
US |